{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:58:37Z","timestamp":1767193117203,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T00:00:00Z","timestamp":1491868800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["KG090959"],"award-info":[{"award-number":["KG090959"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s10549-017-4238-0","type":"journal-article","created":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T03:20:10Z","timestamp":1491880810000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Discerning the clinical relevance of biomarkers in early stage breast cancer"],"prefix":"10.1007","volume":"164","author":[{"given":"Tarah J.","family":"Ballinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawal","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanglong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Lou","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elda","family":"Railey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol B.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan P.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,11]]},"reference":[{"key":"4238_CR1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/oxfordjournals.jncimonographs.a003453","volume":"30","author":"RJ Simes","year":"2001","unstructured":"Simes RJ, Coates AS (2001) Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 30:146\u2013152","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"11","key":"4238_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S1470-2045(01)00559-9","volume":"2","author":"V Duric","year":"2001","unstructured":"Duric V, Stockler M (2001) Patients\u2019 preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile. Lancet Oncol 2(11):691\u2013697. doi: 10.1016\/S1470-2045(01)00559-9","journal-title":"Lancet Oncol"},{"issue":"1","key":"4238_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-16-0908","volume":"23","author":"BP Schneider","year":"2017","unstructured":"Schneider BP, Shen F, Gardner L, Radovich M, Li L, Miller KD, Jiang G, Lai D, O\u2019Neill A, Sparano JA, Davidson NE, Cameron D, Gradus-Pizlo I, Mastouri RA, Suter TM, Foroud T, Sledge GW Jr (2017) Genome-wide association study for anthracycline-induced congestive heart failure. Clin Cancer Res 23(1):43\u201351. doi: 10.1158\/1078-0432.CCR-16-0908","journal-title":"Clin Cancer Res"},{"issue":"22","key":"4238_CR4","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-15-0586","volume":"21","author":"BP Schneider","year":"2015","unstructured":"Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, Jiang G, Vance G, Gardner L, Vatta M, Bai S, Lai D, Koller D, Zhao F, O\u2019Neill A, Smith ML, Railey E, White C, Partridge A, Sparano J, Davidson NE, Foroud T, Sledge GW Jr (2015) Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 21(22):5082\u20135091. doi: 10.1158\/1078-0432.CCR-15-0586","journal-title":"Clin Cancer Res"},{"issue":"7248","key":"4238_CR5","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1136\/bmj.320.7248.1530","volume":"320","author":"M Ryan","year":"2000","unstructured":"Ryan M, Farrar S (2000) Using conjoint analysis to elicit preferences for health care. BMJ 320(7248):1530\u20131533","journal-title":"BMJ"},{"issue":"4","key":"4238_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","volume":"3","author":"D Marshall","year":"2010","unstructured":"Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR (2010) Conjoint analysis applications in health\u2014how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. The Patient 3(4):249\u2013256. doi: 10.2165\/11539650-000000000-00000","journal-title":"The Patient"},{"issue":"4","key":"4238_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J (2011) Conjoint analysis applications in health\u2014a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health 14(4):403\u2013413. doi: 10.1016\/j.jval.2010.11.013","journal-title":"Value Health"},{"issue":"1","key":"4238_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10549-014-2909-7","volume":"145","author":"ML Smith","year":"2014","unstructured":"Smith ML, White CB, Railey E, Sledge GW Jr (2014) Examining and predicting drug preferences of patients with metastatic breast cancer: using conjoint analysis to examine attributes of paclitaxel and capecitabine. Breast Cancer Res Treat 145(1):83\u201389. doi: 10.1007\/s10549-014-2909-7","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"4238_CR9","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23(16):3686\u20133696. doi: 10.1200\/JCO.2005.10.517","journal-title":"J Clin Oncol"},{"issue":"12","key":"4238_CR10","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1002\/1097-0142(20001215)89:12<2521::AID-CNCR2>3.0.CO;2-F","volume":"89","author":"SM Bang","year":"2000","unstructured":"Bang SM, Heo DS, Lee KH, Byun JH, Chang HM, Noh DY, Choe KJ, Bang YJ, Kim SR, Kim NK (2000) Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer 89(12):2521\u20132526","journal-title":"Cancer"},{"issue":"34","key":"4238_CR11","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","volume":"24","author":"SE Jones","year":"2006","unstructured":"Jones SE, Savin MA, Holmes FA, O\u2019Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24(34):5381\u20135387. doi: 10.1200\/JCO.2006.06.5391","journal-title":"J Clin Oncol"},{"issue":"22","key":"4238_CR12","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C, Breast Cancer International Research Group I (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302\u20132313. doi: 10.1056\/NEJMoa043681","journal-title":"N Engl J Med"},{"issue":"16","key":"4238_CR13","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358(16):1663\u20131671. doi: 10.1056\/NEJMoa0707056","journal-title":"N Engl J Med"},{"key":"4238_CR14","unstructured":"R Core Team (2015) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http:\/\/www.R-project.org\/"},{"key":"4238_CR15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/jco.2014.32.15_suppl.500","volume":"32","author":"K Miller","year":"2014","unstructured":"Miller K, O\u2019Neill AM, Dang CT, Northfelt DW, Gradishar WJ, Goldstein LJ et al (2014) Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol 32:500","journal-title":"J Clin Oncol"},{"issue":"10","key":"4238_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","volume":"14","author":"D Cameron","year":"2013","unstructured":"Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14(10):933\u2013942. doi: 10.1016\/S1470-2045(13)70335-8","journal-title":"Lancet Oncol"},{"issue":"4","key":"4238_CR17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1200\/JCO.1995.13.4.858","volume":"13","author":"RP McQuellon","year":"1995","unstructured":"McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B, Yellen SB (1995) Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 13(4):858\u2013868","journal-title":"J Clin Oncol"},{"key":"4238_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/IJWH.S31331","volume":"4","author":"K Beusterien","year":"2012","unstructured":"Beusterien K, Grinspan J, Tencer T, Brufsky A, Visovsky C (2012) Patient preferences for chemotherapies used in breast cancer. Int J Women\u2019s Health 4:279\u2013287. doi: 10.2147\/IJWH.S31331","journal-title":"Int J Women\u2019s Health"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-017-4238-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-017-4238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T18:16:04Z","timestamp":1569003364000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-017-4238-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,11]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["4238"],"URL":"https:\/\/doi.org\/10.1007\/s10549-017-4238-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2017,4,11]]}}}